Sugi Predict

Sugi Predict / Compounds / SCHEMBL2386575

SCHEMBL2386575

SCHEMBL2386575

N#Cc1c(C(F)(F)F)cc(-c2cc(-c3cccc(CC(=O)O)c3)cs2)n(Cc2ccc(F)cc2F)c1=O

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 6/20 0.65
▸ NR1H2 P55055 5/20 0.65
▸ NR1H3 Q13133 5/20 0.65
▸ MAPK14 Q16539 2/20 0.36
▸ RXRB P28702 2/20 0.35
▸ RXRG P48443 2/20 0.35
▸ TNKS O95271 4/20 0.34
▸ TNKS2 Q9H2K2 4/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ PKM P14618 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ PTGS2 P35354 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ KCNK3 O14649 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2388705 0.91 RXRA (0.67) RXRANR1H2NR1H3MAPK14RXRB
SCHEMBL2388561 0.91 RXRA (0.57) RXRANR1H2NR1H3MAPK14TNKS
SCHEMBL2386523 0.90 NR1H2 (0.55) RXRANR1H2NR1H3MAPK14TNKS
SCHEMBL2387464 0.90 RXRA (0.76) RXRANR1H2NR1H3MAPK14RXRB
SCHEMBL2388319 0.90 RXRA (0.64) RXRANR1H2NR1H3MAPK14RXRB
SCHEMBL2390089 0.89 RXRA (0.67) RXRANR1H2NR1H3MAPK14RXRB
SCHEMBL14214292 0.89 RXRA (0.66) RXRANR1H2NR1H3MAPK14TNKS
SCHEMBL2387906 0.88 RXRA (0.61) RXRANR1H2NR1H3RXRBRXRG
SCHEMBL2389743 0.87 RXRA (0.55) RXRANR1H2NR1H3MAPK14TNKS
SCHEMBL2388042 0.86 RXRA (0.59) RXRANR1H2NR1H3MAPK14RXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482366-B2 Modulators of LXR X-CEPTOR THERAPEUTICS, INC. (US) 2009-01-27 — — US claimed
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 — — US claimed
EP-1773337-A2 MODULATORS OF NUCLEAR RECEPTORS Exelixis, Inc. (US) 2007-04-18 — — EP claimed
WO-2006025979-A9 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS INC (US) 2006-04-20 — — WO claimed
WO-2006025979-A2 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS, INC. (US) 2006-03-09 — — WO claimed
US-20050080111-A1 Modulators of LXR X-CEPTOR THERAPEUTICS, INC. (US) 2005-04-14 — — US claimed
US-8013001-B2 Modulators of LXR EXELIXIS, INC. (US) 2011-09-06 — — US disclosed
US-20100056582-A1 Modulators of LXR X-CEPTOR THERAPEUTICS, INC. (US) 2010-03-04 — — US disclosed
US-7482366-B2 Modulators of LXR X-CEPTOR THERAPEUTICS, INC. (US) 2009-01-27 — — US disclosed
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 — — US disclosed
US-20050080111-A1 Modulators of LXR X-CEPTOR THERAPEUTICS, INC. (US) 2005-04-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119488-A1 Modulators Of Nuclear Receptors NR1H2, NR0B1, NR1H3 RXRA 20/4885NR1H2 1/4885NR1H3 3/4885
US-20050080111-A1 Modulators of LXR NR1H2, NR1H3, NR1H4 RXRA 16/4885NR1H2 1/4885NR1H3 2/4885
US-20100056582-A1 Modulators of LXR NR1H2, NR1H3, NR1H4 RXRA 16/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.